|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
FR2711523B1
(fr)
|
1993-10-26 |
1996-02-16 |
Transgene Sa |
Procédé de préparation d'un aérosol viral.
|
|
JPH10501681A
(ja)
|
1994-02-22 |
1998-02-17 |
ダナ−ファーバー キャンサー インスティチュート |
核酸送達システムならびにその合成および使用方法
|
|
US5837520A
(en)
|
1995-03-07 |
1998-11-17 |
Canji, Inc. |
Method of purification of viral vectors
|
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
JP2000514290A
(ja)
|
1996-07-01 |
2000-10-31 |
ローヌ―プーラン・ロレ・エス・アー |
組換えアデノウイルスの製造方法
|
|
EP0968284B1
(en)
|
1996-11-20 |
2006-12-13 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
IL130198A
(en)
|
1996-12-13 |
2005-09-25 |
Schering Corp |
Methods for purifying viruses
|
|
FR2763958A1
(fr)
|
1997-05-29 |
1998-12-04 |
Transgene Sa |
Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
|
|
AU707186B2
(en)
|
1997-07-01 |
1999-07-01 |
Transgene S.A. |
Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
|
|
AU752658B2
(en)
|
1998-05-06 |
2002-09-26 |
Association Francaise Contre Les Myopathies |
Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
|
|
JP3864610B2
(ja)
|
1998-05-21 |
2007-01-10 |
旭硝子株式会社 |
水分散型撥水撥油剤組成物およびその製造方法
|
|
EP0998945A1
(en)
|
1998-09-30 |
2000-05-10 |
Transgene S.A. |
Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
|
|
AU779267B2
(en)
|
1998-12-31 |
2005-01-13 |
Centelion S.A.S. |
Method for separating viral particles
|
|
CA2364934C
(fr)
|
1999-02-22 |
2011-10-18 |
Transgene S.A. |
Procede d'obtention d'une preparation virale purifiee
|
|
EP1156832A1
(en)
|
1999-12-28 |
2001-11-28 |
Transgene S.A. |
Use of lithium (li?+ ) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
|
|
WO2004029212A2
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
AU2004221760B2
(en)
|
2003-03-21 |
2010-03-18 |
Roche Innovation Center Copenhagen A/S |
Short interfering RNA (siRNA) analogues
|
|
ES2356154T3
(es)
|
2003-07-21 |
2011-04-05 |
Transgene S.A. |
Citoquinas multifuncionales.
|
|
WO2005073378A1
(en)
|
2004-01-30 |
2005-08-11 |
Santaris Pharma A/S |
MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
|
|
US7361468B2
(en)
*
|
2004-07-02 |
2008-04-22 |
Affymetrix, Inc. |
Methods for genotyping polymorphisms in humans
|
|
US20080213891A1
(en)
|
2004-07-21 |
2008-09-04 |
Alnylam Pharmaceuticals, Inc. |
RNAi Agents Comprising Universal Nucleobases
|
|
EP1948674A4
(en)
|
2005-11-02 |
2009-02-04 |
Protiva Biotherapeutics Inc |
MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
|
|
WO2007124452A2
(en)
|
2006-04-20 |
2007-11-01 |
The Regents Of The University Of California |
Methods for expressing multiple sirna and shrna from a single vector
|
|
WO2010030396A2
(en)
|
2008-09-15 |
2010-03-18 |
Stanford University |
Novel shrna gene therapy for treatment of ischemic heart disease
|
|
WO2011111072A2
(en)
|
2010-03-10 |
2011-09-15 |
Transgene Biotek Ltd. |
Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer
|
|
US9163236B2
(en)
|
2010-12-06 |
2015-10-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer
|
|
SG10201604810UA
(en)
*
|
2012-02-07 |
2016-08-30 |
Global Bio Therapeutics Inc |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
|
US20130259927A1
(en)
|
2012-04-02 |
2013-10-03 |
Gradalis, Inc. |
Ewing's Sarcoma Bifunctional shRNA Design
|
|
ES2809199T3
(es)
*
|
2012-06-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de UBE3A-ATS
|
|
CN105120901A
(zh)
|
2012-07-11 |
2015-12-02 |
宾夕法尼亚大学托管会 |
Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
|
|
WO2014052855A1
(en)
|
2012-09-27 |
2014-04-03 |
Population Diagnostics, Inc. |
Methods and compositions for screening and treating developmental disorders
|
|
WO2015089443A2
(en)
*
|
2013-12-12 |
2015-06-18 |
The Brigham And Women's Hospital, Inc. |
Treating neurodegenerative disease
|
|
WO2016086104A1
(en)
*
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
|
HK1258434A1
(zh)
*
|
2015-11-12 |
2019-11-08 |
F. Hoffmann-La Roche Ag |
来自灵长类物种的标准化神经元细胞测定试验
|
|
WO2017189963A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
CN118950038A
(zh)
|
2018-09-07 |
2024-11-15 |
科慕埃弗西有限公司 |
使用含氯烃从氟卤化锑催化剂除去氟
|
|
EP3833398A4
(en)
|
2018-09-21 |
2021-12-22 |
University of Connecticut |
COMPOSITIONS AND METHODS OF RESTORING PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN'S SYNDROME IN HUMANS
|